9.00
+4.41%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xilio Therapeutics
From its filings with the US Securities and Exchange Commission
Xilio Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker XLO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $43.8m and a net loss of $35.0m. At that date it held total assets of $154.7m and shareholders' equity of $35.3m.
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Our integrated biology and protein engineering approach enables us to design and develop highly potent, masked biologics that are activated, or unmasked, by tumor-specific proteases within the tumor microenvironment. We are currently advancing multiple programs in preclinical and clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.
Cancer immunotherapy has demonstrated compelling efficacy, including the ability to generate complete responses and the potential to provide meaningful durability of response and improvements in survival. However, severe side effects have limited the use and potential of most systemically active I-O agents.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Oct 2021
- Employees
- 81
- Website
- xiliotx.com ↗
- Head office
- 828 WINTER STREET, WALTHAM, MA, 02451
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Paul ClancyIndependent Chairman of the Board$89,058
- Dr. Rene RussoPresident, Chief Executive Officer, Director$1.5m
- Mr. Christopher FrankenfieldChief Financial Officer and Operating Officer$1.0m
- Mr. Kevin BrennanSenior Vice President - Finance & Accounting
- Dr. Katarina LuptakovaChief Medical Officer$747,504
- Dr. Akintunde BelloDirector
- Ms. Sara BonsteinIndependent Director$69,058
- Dr. Aoife BrennanIndependent Director$63,507
- Dr. Daniel CurranIndependent Director$60,256
- Dr. Robert RossIndependent Director$59,058
- Ms. Christina RossiIndependent Director$71,558
- Dr. James ShannonIndependent Director$63,507
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xilio Therapeutics has 81 employees focused on biotechnology innovation in Waltham, Massachusetts.
- XTX101 is in a Phase I clinical trial for advanced solid tumors with a novel tumor-activated mechanism.
- XTX202 is an engineered IL-2 molecule targeting CD8+ T cells and NK cells without regulatory T cell stimulation.
Weaknesses
- Xilio Therapeutics has only 81 employees, which may limit research and development capacity.
- The company's clinical-stage product candidates are still in early phases of development.
- Xilio Therapeutics' IPO was on 22 October 2021, indicating limited market history.
Opportunities
- XTX101's tumor-activated mechanism could improve therapeutic index over existing anti-CTLA-4 therapies.
- XTX202's engineered IL-2 molecule may offer better efficacy for cancer treatments.
- The biotechnology sector in the US continues to grow with increasing investment in cancer therapies.
Threats
- Xilio Therapeutics' clinical-stage products face regulatory hurdles in the US biotechnology sector.
- Competition in the biotechnology industry could impact Xilio's market position.
- The company's limited employee count may hinder scalability in a competitive market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.